Island Pharmaceuticals (ASX:ILA) raised a total of AU$2.7 million via the exercise of 45.3 million listed options, which expired March 14, according to a Wednesday Australian bourse filing.
The options were issued to shareholders who participated in the firm's fully underwritten rights issue in March 2024.
The additional funds raised will be used to support the clinical development activities for ISLA-101, its candidate for the prevention and treatment of dengue fever.
Its shares rose over 2% on Wednesday's close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.